laboratory and clinical studies that the benefits of thrombolytic therapy are conferred by restoration of patency of the infarct-related artery. [6] [7] [8] [9] Recently, Abbottsmith and coworkers10 have reported that salvage angioplasty after failed thrombolysis improves outcome in these patients. Thus, invasive means are valuable in selected patients to establish coronary artery patency.11,2 Rescue thrombolysis with readministration of the same or a different thrombolytic agent may also have a role after failed initial thrombolytic therapy. 13 On the other hand, acute routine angiography in all patients receiving thrombolytic therapy for acute infarction is unnecessary and may eventually cause harm to some.14-16 Hence, reliable methods other than angiography are needed to detect coronary reperfusion early during the hospital course. In previous studies, the normalization of ST segment elevation in the surface ECG,17-21 the occurrence of reperfusion arrhythmias,19,22-24 the resolution of infarct-related chest pain,25,26 and various cardiac enzymes have been used for this purpose. For example, a short time to peak creatine kinase (CK)27 or CK-MB concentration28,29 has been proposed as an indicator of reperfusion. More recently, new serum markers such as myoglobin,28'30 CK-MB isoforms,31 and the specific cardiac antigen troponin T32 have become available and have been examined in small groups of patients with acute myocardial infarction. Up to now, however, the value of these new reperfusion markers has not been vigorously evaluated, and they have not been compared with each other in a reasonably large cohort of patients undergoing thrombolysis. The aims of the present prospective study, therefore, were 1) to develop simple indexes for success or failure of reperfusion therapy according to the initial CK and CK-MB time-activity curves and 2) to evaluate whether new reperfusion markers such as myoglobin and troponin T yield a higher diagnostic accuracy in prediction of thrombolysis-induced reopening of the infarct-related artery compared with conventional serum markers. Particular 
Serum Markers
Blood samples (10 mL) were taken before initiation of thrombolysis, every 15 minutes for the first 90 minutes after start of therapy, every 30 minutes for the first 4 hours, every 4 hours up to 24 hours, and every 8 hours up to 72 hours. The samples were stored at room temperature to allow clotting and frozen at -20°C after centrifugation until analysis. Samples were analyzed by investigators who were unaware of the angiographic results. Plasma total CK activity was assayed according to the method of Rosalki. 33 The mass of the CK-MB isoenzyme was determined by means of a rapid fluorometric enzyme immunoassay based on a two-site sandwich immunoassay methodology (Baxter Stratus, Miami, Fla. Figure 1 , raw data from a patient with successful reperfusion and from another without reperfusion are shown to illustrate the technique of slope determinations.
Clinical Reperfusion Markers
Resolution of maximal ST segment elevation was judged from two surface ECGs taken before and 120 minutes after start of thrombolysis. In addition, Holter monitoring was started before injection of the thrombolytic agent for assessment of reperfusion arrhythmias within the first 90 minutes. Accelerated idioventricular rhythm (AIVR) was defined by a heart rate of < 100 beats per minute, a long coupling interval, a regular configuration and rate, and termination by sinus escape. Sinus bradycardia was defined by a heart rate of <55 beats per minute. Patients were also interviewed for the severity of chest pain on a subjective scale ranging from 0 to 10 before and 90 minutes after thrombolysis.
Statistical Methods
Values are given as mean±+SD. The Minutes after start of thronmbolysis groups. Linear regression analysis was performed for related parameters, and coefficients of correlations were calculated and tested for significance. The for the time to peak CK-MB, myoglobin, and troponin T were retrospectively defined at 10, 3, and 15 hours after start of thrombolysis, respectively, since no previously described cutoff values were available from the literature. Accordingly, the cutoffs for the absolute rise of each marker over the first 90 minutes of therapy were chosen as 10, 150, and 0.2 ng* mL-'* hr-' for CK-MB, myoglobin, and troponin T, respectively. To allow comparison with the CK data, these numbers were chosen to represent similarly good but not optimal cutoffs. Since potential bias concerning the choice of a single cutoff cannot be excluded (even if prospectively defined), sensitivity and specificity data are represented over the entire cutoff range in the applicable figure (Figure 2 40 and 80 units * -hr-t ( Figure 2 ). An inverse correlation was found between CK slope and maximum (r= -0.40, p<O.0Ol).
Analysis of CK-MB Mass
Peak CK-MB averaged 216±151 ng/mL for patients with a patent versus 167±130 units/L for patients with an occluded infarct artery (p=NS). Time to peak was similar to that of CK and averaged 7.5±4.1 hours in patients with versus 12.0±5.3 hours for patients without coronary artery patency (p=0.004). Sensitivity and specificity for prediction of vessel patency at the chosen cutoff of 10 hours were 78% and 65% for CK-MB maximum, respectively. The best range of cutoffs was 8.5-12 hours. For the slope of CK-MB, the range of acceptable cutoffs was 15-20 ng . mL`* hr-1 ( Figure 2 and Table 1 (Figure 2 ). This range was also narrow for the analysis of troponin T slopes, for which sensitivity was 80% at a specificity of only 65% for the predefined cutoff of 0.2 ng * mL-* hr-1. ROC curve areas were 0.80 for both maximum and slope analysis of troponin T ( Figure 3 , Table 1 (Figure 3 , Table 1 ). The difference in ROC areas between myoglobin and CK was close to significance (p=O0.07), whereas the difference in CK-MB slope was not significant (p=0.23). As demonstrated in Figure 4 , regression analysis disclosed a significant correlation between time to myoglobin and CK maximum and between time to troponin T and CK maximum (r=0.59 for both correlations). With respect to the time-activity curves, analyses of CK, CK-MB, and troponin T were comparable, revealing pathological findings in approximately 60-65% of patients at 60 minutes and in 90% at 120 minutes after the initiation of thrombolysis ( Figure 5 ). minutes and 91% at 60 minutes after start of therapy ( Figure 5 ).
Comparison With Other Clinical Reperfusion Markers Table 2 demonstrates that resolution of ST segment elevation and the occurrence of reperfusion arrhythmias were also predictors of coronary artery patency. The calculated x2 values indicate that both markers were comparable to those serum markers with the lowest predictive values for coronary artery patency (Tables 1 and 2 rapid assay using turbidimetry has recently been introduced into clinical practice.4344 Third, myoglobin concentration exhibited the earliest rise of all serum markers examined after initiation of therapy. Although the purpose of the present investigation was not to examine the accuracy of serum markers with respect to diagnosis of myocardial infarction but rather the efficacy of thrombolysis, this protein may offer an additional diagnostic advantage. The usefulness of myoglobin for noninvasive prediction of infarct-artery patency has recently been confirmed by other investigators.45 However, Clemmensen and coworkers45 reported no comparison with other serodiagnostic markers in their study. In the present investigation, CK maximum and CK-MB maximum yielded relatively good diagnostic information regarding coronary artery patency as well. However, compared with the time elapsed to reach peak myoglobin levels, it took four to five times as long to reach maximal concentrations of these enzymes. This time frame would therefore significantly reduce the chances to salvage jeopardized myocardium by means of invasive procedures. It has been shown previously that combined analysis of noninvasive markers (i.e., peak CK, resolution of ST segment elevation, occurrence of reperfusion arrhythmias) can improve assessment of success or failure of thrombolytic therapy. 19 In the present study, other clinical reperfusion markers did not add significantly to the predictive power of myoglobin slope analysis, indicating the particular strength of this marker.
According to the results of the present study, troponin T offers no advantages for noninvasive prediction of coronary reperfusion in patients undergoing thrombolysis (Table 1) . However, troponin T analysis was helpful in the four patients suffering from ventricular fibrillation. In these patients, CK values were distorted by the enzyme release from skeletal muscles caused by the defibrillation shock, whereas troponin T levels were not affected because of the high specificity of this marker for myocardial tissue. 36 
Clinical Implications
The present study demonstrates that analysis of the early initial rise of several serum markers is as accurate as determination of the time elapsed to reach their peak concentration with respect to noninvasive prediction of success or failure of thrombolysis in patients with acute infarction. This allows early noninvasive prediction of coronary artery patency in the majority of patients within the first 2 hours after initiation of thrombolytic therapy. These time limits allow for measures such as rescue angioplasty that aim to salvage myocardium. Early slope analysis of myoglobin appears to be superior to the other serum markers examined and, in addition, exhibits the most rapid concentration increase of all markers evaluated.
